PTCT Relative Valuation
PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTCT is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for PTCT's competitors is 19.28, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT) exhibits a P/S ratio of 4.71, which is -75.58% above the industry average. Given its robust revenue growth of 459.73%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is PTC Therapeutics Inc (PTCT) currently overvalued or undervalued?
What is PTC Therapeutics Inc (PTCT) fair value?
How does PTCT's valuation metrics compare to the industry average?
What is the current P/B ratio for PTC Therapeutics Inc (PTCT) as of May 20 2025?
What is the current FCF Yield for PTC Therapeutics Inc (PTCT) as of May 20 2025?
What is the current Forward P/E ratio for PTC Therapeutics Inc (PTCT) as of May 20 2025?